NOVARTIS AG NVS Income Statement

Dec'17	Dec'16	Dec'15
Net sales to third parties from continuing operations
49,109	48,518	49,414
Sales to discontinued segments
-	-	26
Net sales to third parties
49,109	48,518	49,440
Other revenues
1,026	918	947
Cost of goods sold
17,175	17,520	17,404
Gross profit from continuing operations
32,960	31,916	32,983
Marketing and Sales
12,861	11,998	11,772
Research and Development
8,972	9,039	8,935
General and Administration
2,136	2,194	2,475
Other income
1,969	1,927	2,049
Other expense
2,331	2,344	2,873
Operating income from continuing operations
8,629	8,268	8,977
Income from associated companies
1,108	703	266
Interest expense
777	707	655
Other financial income and expense
39	-447	-454
Income before taxes from continuing operations
8,999	7,817	8,134
Taxes
1,296	1,119	1,106
Net income from continuing operations
7,703	6,698	7,028
Net income/loss from discontinued operations
-	-	10,766
Net income
7,703	6,698	17,794
Attributable to
Shareholders of Novartis AG
7,703	6,712	17,783
Non-controlling interests
0	-14	11
Basic earnings per share [abstract]
Basic earnings per share, Continuing operations
3.28	2.82	2.92
Basic earnings per share, Discontinued operations
-	-	4.48
Total basic earnings per share
3.28	2.82	7.40
Diluted earnings per share [abstract]
Diluted earnings per share, Continuing operations
3.25	2.80	2.88
Diluted earnings per share, Discontinued operations
-	-	4.41
Total diluted earnings per share
3.25	2.80	7.29